Nexstim Toekomstige groei

Future criteriumcontroles 4/6

De verwachting is dat Nexstim de winst en omzet met respectievelijk 75.1% en 15.7% per jaar zal laten groeien, terwijl de winst per aandeel naar verwachting zal groeien met 75.6% per jaar.

Belangrijke informatie

75.1%

Groei van de winst

75.6%

Groei van de winst per aandeel

Medical Equipment winstgroei	25.7%
Inkomstengroei	15.7%
Toekomstig rendement op eigen vermogen	n/a
Dekking van analisten	Low
Laatst bijgewerkt	22 Oct 2024

Recente toekomstige groei-updates

Recent updates

Winst- en omzetgroeiprognoses

HLSE:NXTMH - Toekomstschattingen van analisten en financiële gegevens uit het verleden (EUR Millions )
Datum	Inkomsten	Inkomsten	Vrije kasstroom	Geldmiddelen uit operationele activiteiten	Gem. Aantal analisten
12/31/2026	14	2	2	3	1
12/31/2025	12	1	2	2	1
12/31/2024	9	0	2	2	1
6/30/2024	9	-1	-2	0	N/A
3/31/2024	9	-1	-3	-1	N/A
12/31/2023	9	-1	-4	-2	N/A
9/30/2023	8	-2	-4	-3	N/A
6/30/2023	6	-3	-4	-3	N/A
3/31/2023	9	-1	-2	-1	N/A
12/31/2022	11	1	0	1	N/A
9/30/2022	11	2	0	2	N/A
6/30/2022	12	3	0	2	N/A
3/31/2022	10	1	-2	0	N/A
12/31/2021	8	-1	-4	-2	N/A
9/30/2021	7	-2	-4	-3	N/A
6/30/2021	6	-4	-4	-3	N/A
3/31/2021	5	-4	-3	-3	N/A
12/31/2020	4	-4	-3	-3	N/A
9/30/2020	4	-4	-4	-4	N/A
6/30/2020	4	-4	-5	-5	N/A
3/31/2020	4	-6	-6	-6	N/A
12/31/2019	3	-7	-8	-7	N/A
9/30/2019	3	-7	-8	-7	N/A
6/30/2019	3	-7	-7	-7	N/A
3/31/2019	3	-7	-7	-6	N/A
12/31/2018	3	-6	-7	-6	N/A
9/30/2018	3	-6	-6	-6	N/A
6/30/2018	3	-6	-6	-6	N/A
3/31/2018	3	-7	N/A	-6	N/A
12/31/2017	3	-7	N/A	-5	N/A
9/30/2017	3	-7	N/A	-5	N/A
6/30/2017	3	-6	N/A	-5	N/A
3/31/2017	3	-6	N/A	-6	N/A
12/31/2016	3	-7	N/A	-7	N/A
9/30/2016	3	-8	N/A	-8	N/A
6/30/2016	3	-9	N/A	-10	N/A
3/31/2016	3	-10	N/A	-10	N/A
12/31/2015	3	-10	N/A	-10	N/A
9/30/2015	3	-10	N/A	-10	N/A
6/30/2015	3	-10	N/A	-11	N/A
3/31/2015	2	-10	N/A	-9	N/A
12/31/2014	2	-10	N/A	-8	N/A
9/30/2014	2	-9	N/A	-6	N/A
6/30/2014	2	-7	N/A	-5	N/A
3/31/2014	2	-6	N/A	-4	N/A
12/31/2013	2	-5	N/A	-4	N/A

Toekomstige groeivoorspellingen analisten

Verdiensten versus spaarpercentage: Er wordt voorspeld dat NXTMH de komende 3 jaar winstgevend zal worden, wat wordt beschouwd als een snellere groei dan de spaarquote ( 1.3% ).

Winst versus markt: Er wordt verwacht dat NXTMH de komende 3 jaar winstgevend zal worden. Dit wordt gezien als een groei die boven het gemiddelde van de markt ligt.

Hoge groeiwinsten: Er wordt verwacht dat NXTMH binnen 3 jaar winstgevend zal worden.

Omzet versus markt: De omzet van NXTMH ( 15.7% per jaar) zal naar verwachting sneller groeien dan de markt Finnish ( 2.6% per jaar).

Hoge groei-inkomsten: De omzet van NXTMH ( 15.7% per jaar) zal naar verwachting langzamer groeien dan 20% per jaar.

Groeiprognoses winst per aandeel

Toekomstig rendement op eigen vermogen

Toekomstige ROE: Onvoldoende gegevens om te bepalen of het rendement op eigen vermogen van NXTMH naar verwachting over 3 jaar hoog zal zijn

Nexstim Toekomstige groei

Future criteriumcontroles 4/6

Belangrijke informatie

Recente toekomstige groei-updates

Nexstim Plc Updates Earnings Guidance for the Year 2023

Consensus EPS estimates fall by 33%

Price target decreased to €4.40

Nexstim Plc Provides Earnings Guidance for the Year 2022

Forecast to breakeven in 2022

Forecast to breakeven in 2022

Recent updates

Nexstim Plc to Report Fiscal Year 2024 Results on Feb 27, 2025

Nexstim plc Receives Approval from Health Canada for the Marketing and Commercial Distribution of Its NBS 6 System for the Treatment of Major Depressive Disorder

Nexstim Plc Updates Earnings Guidance for the Year 2023

Nexstim Plc, Annual General Meeting, Mar 28, 2024

Nexstim Plc to Report Fiscal Year 2023 Final Results on Mar 06, 2024

Nexstim Plc Releases New System Functionalities for Research Use in Europe

Nexstim Plc to Report Q3, 2023 Results on Oct 27, 2023

Nexstim plc Announces Board Appointments

Nexstim Plc to Report Fiscal Year 2023 Results on Feb 27, 2024

Nexstim plc Provides Overview of Pilot Study Results in Treatment of Severe Depression with Nexstim Nbt®? System At Kuopio University Hospital

Nexstim Applies for Delisting Regarding the Secondary Listing of its Shares from Nasdaq First North Growth Market Sweden

Consensus EPS estimates fall by 33%

Nexstim Plc, Annual General Meeting, Mar 31, 2023

Is Now The Time To Look At Buying Nexstim Plc (HEL:NXTMH)?

Price target decreased to €4.40

Nexstim Reports Excellent Treatment Outcomes of over 400 MDD Patients in Patient Registry

Nexstim plc Appoints Tero Weckroth as A New Member of the Nomination Committee

Nexstim's (HEL:NXTMH) Promising Earnings May Rest On Soft Foundations

At €4.73, Is Nexstim Plc (HEL:NXTMH) Worth Looking At Closely?

First half 2022 earnings released

Nexstim Plc Provides Earnings Guidance for the Year 2022

Is Nexstim (HEL:NXTMH) A Risky Investment?

High number of new and inexperienced directors

Forecast to breakeven in 2022

High number of new and inexperienced directors

Forecast to breakeven in 2022

Forecast to breakeven in 2022

Full year 2021 earnings: Revenues exceed analyst expectations

Nexstim Reaches Over 300 Completed Treatment Sessions – Continues to Report a Remission Rate Greater than 50% of MDD Patients in the Patient Registry

Nexstim Plc Announces Results of the Pilot Study in Chronic Pain Treatment At Helsinki University Hospital

Nexstim (HEL:NXTMH) Has Debt But No Earnings; Should You Worry?

Nexstim Plc Receives System Orders from Existing Hospital Customers in Finland

Nexstim Announces Continuation of Pilot Study in Treatment of Severe Depression at Kuopio University Hospital

Is Nexstim (HEL:NXTMH) Using Debt In A Risky Way?

First half 2021 earnings released: €0.17 loss per share (vs €1.25 loss in 1H 2020)

Nexstim Plc Provides Update on Pilot Study in Chronic Pain Treatment at Helsinki University Hospital

Nexstim Plc Continues to Report Very Promising MDD Treatment Outcomes with Remission Rate Greater Than 50%

Nexstim Plc Granted Authorization for Commercial Distribution of NBS System in Australia

Nexstim Gives an Update on its Promising Treatment Results of Major Depressive Disorder

Nexstim plc Receives Two NBS System Orders from Hospitals in Norway and the Us

Nexstim plc Provides Encouraging Results of the Initial Pilot Study in Severe Depression At Kuopio University Hospital

Full year 2020 earnings released

Revenue and earnings beat expectations

German University Hospital Orders Nexstim NBS System with NexSpeech

Rohan Hoare and Tomas Holmberg No Longer Be Available to Nexstim Plc's Board of Directors for the Period 2021-2022

Nexstim plc Receives Three New NBS System Orders

Nexstim Plc Receives Two New NBT® System Purchase Orders in the United States

Nexstim plc Provides an Update on the Pilot Study in Severe Depression At Kuopio University Hospital

Nexstim Plc Receives an Order and Signs Purchase Agreement to Develop Two Prototype Systems Enabling Introduction of Novel Research Tool for Probing and Diagnosing the Brain

Nexstim plc Continues to Report Promising Results in Quickly Growing Number of Patients Completing SmartFocus rTMS Treatment of Major Depressive Disorder

Pilot Study for New Depression Treatment Protocol with Nexstim NBT® System Starts in Kuopio University Hospital

Earnings released

Winst- en omzetgroeiprognoses

Toekomstige groeivoorspellingen analisten

Groeiprognoses winst per aandeel

Toekomstig rendement op eigen vermogen

Ontdek groeibedrijven